Table 5 Univariate sensitivity analyses of fesoterodine versus tolterodine ER or solifenacin

Base-case scenario: Results weeks 52, societal perspective

Weeks 52, health system perspective

Weeks 12, health system perspective

Weeks 12, societal perspective

+/- 25% in OAB-related co morbidities costs

+/- 25% in OAB-related co morbidities rate per year in continent patients

+/- 25% in OAB-related co morbidities rate per year in incontinent patients

+/- 25% in utility estimates

+/- 25% in % of responders to fesoterodine 4 mg and solifenacin 5 mg that titrate to the higher dose at week 4

+/- 25% in % of non-responders to fesoterodine 4 mg and solifenacin 5 mg that do not to titrate to the higher dose at week 4

+25% in % continent patients at week 12

- 25% in % continent patients at week 12

+/- 25% in % continent patients at week 52

+/- 25% in medical services costs*

Medical services utilization

   +/- 25% % of incontinent patients using pads

   +/- 25% No. pads/day for incontinent patients

   +/- 25% in # GP visits/month

   +/- 25% in # specialist visits/month

   +/- 25% in # lab tests/month

Productivity data

   +/- 25% in decrease in hours worked due to incontinence

   +/- 25% in reduced daytime productivity due to nocturia

   +/- 25% in % employed in population

   +/- 25% in average hourly wage